The mCRPC section's reorganization by prior treatment exposure reflects how ARPI and docetaxel use in the hormone-sensitive ...

First patient dosing occurred for JANX011 (NCT07291323), a CD19-targeted bispecific inaugurating the ARM platform to enable ...

The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.

The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves a combination of therapies, including chemotherapy, hormone therapy, immunotherapy, and different medications that ...

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...

Enzalutamide may offer a survival advantage compared with abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC), according to 2 US studies of older men. Overall survival ...

Radioligand therapy (RLT) with actinium-225 targeting prostate-specific membrane antigen (225 Ac-PSMA) had a "substantial antitumor effect" in heavily pretreated metastatic castration-resistant ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any ...

(RTTNews) - Pfizer (PFE), on Thursday announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA or talazoparib in combination with XTANDI or enzalutamide for the treatment of metastatic ...

Patients with detectable ctDNA before treatment had a shorter duration of clinical benefit and shorter overall survival. Having detectable circulating tumor DNA (ctDNA) before treatment is associated ...

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

The last time I spoke about INmune Bio (INMB) it was with a Seeking Alpha article entitled "INmune Bio: Alzheimer's Disease Treatment Lottery Ticket". With this article, I noted its prospects about ...